Tuesday, March 01, 2016

The Malignant Protein Puzzle

By: Lary C. Walker, Ph.D., and Mathias Jucker, Ph.D.

Editor’s Note: When most people hear the words malignant and brain, cancer immediately comes to mind. But our authors argue that proteins can be malignant too, and can spread harmfully through the brain in neurodegenerative diseases that include Alzheimer's, Parkinson's, CTE, and ALS. Studying how proteins such as PrP, amyloid beta, tau, and others aggregate and spread, and kill brain cells, represents a crucial new frontier in neuroscience.

 

 Cerebrum - spotlight image - The Malignant Protein Puzzle (March 2016)
 Illustration by Katie O’Leary

O n the Australian island of Tasmania around 20 years ago, a disfiguring, fatal cancer of the face was reported to be rapidly spreading among Tasmanian devils. The disease, known as devil facial-tumor disease, happens to be an extraordinary instance of infectious cancer. It is caused not by a virus but by the direct transfer of cancer cells from one devil to another, possibly through biting. 1 And it is not unique to devils; other examples of unusual infectious cancers have been described in species such as dogs 2 and clams. 3

These curious cases reveal that some cancer cells can “infect” receptive hosts, but they by no means indicate that all malignancies should be treated as infectious diseases. The great majority of cancers arise within the body of the host when normal cells transform and proliferate uncontrollably. Infectious cancers do, however, highlight the impartial resourcefulness of biology in both health and disease.

We now believe that many of the neurodegenerative diseases that increasingly plague modern humans bear an intriguing similarity to cancer, except that the disease agents that proliferate in these brain disorders are not transformed cells, but rather transformed proteins that have folded into the wrong shape. Such “malignant” proteins are key players in such devastating diseases as Alzheimer’s, Parkinson’s, Huntington’s, frontotemporal dementia, chronic traumatic encephalopathy (CTE), amyotrophic lateral sclerosis (ALS), and Creutzfeldt-Jakob disease (CJD). Most of these maladies are thought to be non-contagious under ordinary circumstances, but CJD and its variants have been transmitted to humans by tainted meat, cannibalism, and tissue transplants, and research suggests that other disease-linked malignant proteins can in some circumstances transmit their properties from one organism to another.

As in the case of cancerous cells, though, these rogue proteins almost always emerge and propagate within the affected host. Once the misfolded proteins gain a foothold in the nervous system, they effectively compel normal versions of the same protein to adopt the same malformed state. In this faulty configuration, the proteins stick to one another and, in a molecular chain-reaction, structurally corrupt like molecules that are generated in the course of normal cellular metabolism. In many instances, the final products of this process are clumps of the protein called amyloid (Figure 1). Central to this process is what we call seeded protein aggregation (seeding for short), a surprisingly common disease mechanism that first came to light with the discovery that protein seeds called prions can act as infectious agents.

 Cerebrum - Figure 1 - The Malignant Protein Puzzle (March 2016)
Figure 1.   The steps leading from a single protein molecule to clumps of amyloid. The misfolded proteins act as seeds that accelerate the crystallization-like disease process. The seeds can vary in size, and very small assemblies called oligomers can be particularly toxic to cells.  In prion diseases, the seeds can sometimes be transferred from one organism to another (“infection”).

Image courtesy of Lary Walker/Mathias Jucker

The Prevailing Prion

The improbable tale of infectious proteins began in the 1730s, when reports of a slowly progressing and ultimately fatal disease of sheep first appeared in the European scientific literature. British farmers called the disease scrapie because affected sheep were seen to scrape the wool from their skin by compulsively rubbing against farmyard objects. The farmers suspected even then that scrapie was contagious, but it wasn’t until the 1930s that transmission of the disease was demonstrated experimentally by Jean Cuillé and Paul-Louis Chelle in France. 4,5 To establish infectivity, Cuillé and Chelle injected homogenized nervous tissue from scrapie-afflicted donor sheep into healthy host sheep. Infectious illnesses usually emerge within days or weeks, but earlier experiments had failed to demonstrate transmission of scrapie in this timeframe. Cuillé and Chelle, however, were patient; the sheep that they injected with scrapie-tainted tissue finally succumbed to the disease more than a year later.

Thus began a long and prickly debate about the nature of the scrapie agent: What kind of infectious pathogen causes disease only after months or years of incubation? Furthermore, infections usually announce their presence with inflammation and fever, yet scrapie showed no such signs. The term “slow virus” was adopted by many, but evidence gradually mounted that the culprit was not a virus at all, but rather, just possibly, an infectious protein.

Interest in the problem intensified in the 1960s when D. Carleton Gajdusek and his colleagues made the Nobel Prize-winning discovery that, like scrapie, two rare human neurodegenerative diseases, kuru and Creutzfeldt-Jakob disease, are transmissible with very long incubation periods. 6   By then it was becoming clear that the agent of infection was strange indeed. Radiobiological experiments performed by Tikvah Alper strongly suggested that the agent did not require nucleic acids to replicate, 7 and the mathematician John Griffith described, prophetically, how a protein-only agent might multiply using the host’s genetic machinery to generate more protein. 8 In 1982, Stanley Prusiner crystallized the protein-only concept (and enraged its opponents 9 ) by naming the scrapie agent a “proteinaceous infectious particle,” or “prion.” In subsequent years, Prusiner’s group, along with a growing cadre of allies, amassed persuasive experimental support for the prion concept, for which Prusiner was awarded the Nobel Prize in 1997. Although echoes of the old debate about the causative agent still sometimes find their way into print, 10 the prion paradigm has prevailed, and today is evolving into a far-reaching new concept of disease. 11-14

Assembling Into Amyloid

The prions of CJD and scrapie are submicroscopic assemblies of a natural mammalian protein known as prion protein, or PrP. Prions consist of misfolded versions of PrP that can seed the formation of similar assemblies by a process resembling the seeded crystallization seen in some chemical reactions 15 ( Figure 1 ). In this sense, PrP prions can be viewed as malignant proteins that multiply and spread within the nervous system, eventually causing neurological dysfunction and death. In humans, PrP prions trigger progressive, fatal neurodegenerative disorders that include CJD, kuru, Gerstmann-Sträussler-Scheinker disease, and fatal insomnias. 16 In nonhuman species, the PrP prion diseases include scrapie, bovine spongiform encephalopathy (“mad cow disease”), and chronic wasting disease (CWD) of North American deer, elk, and moose. 16,17

Cerebrum - Figure 2 - The Malignant Protein Puzzle (March 2016) (feat)
Figure 2: Spongiform vacuoles (here seen in the microscope as holes) in a thin slice of the brain of a patient who died of Creutzfeldt-Jakob disease, a prion disease. Neurons and the nuclei of other brain cells are darkly stained.
 
Image courtesy of 
Lary Walker/Mathias Jucker

Before the discovery of prions, these diseases often were called spongiform encephalopathies due to the appearance of sponge-like vacuoles in the brain (Figure 2). Despite being caused by just one type of protein—PrP—different prion diseases display remarkably different clinical and pathological signs, and these differences appear to be related to distinct molecular features of the prions.18 The exact mechanisms by which nervous tissues are damaged in prion diseases (and other neurodegenerative disorders) remain incompletely understood—and that poses a pressing challenge for future research. 

The enigma of infectious proteins was deepened with the discovery that PrP prion diseases also can be caused by mutations in the gene that encodes PrP.9,12 These hereditary forms of prion disease, ironically, helped to establish the protein-only hypothesis of the infectious agent, as they confirmed the importance of normally generated PrP in the creation of new prions. In other words, hereditary (and presumably also spontaneous) PrP prion disease begins when prions are formed by the misfolding of PrP that is generated by cells inside the body. Infectious prion disease, in contrast, results when external prions invade the body of the host. But in all cases, once the process begins, the abnormal prion protein accumulates in the nervous system and triggers the impairment and death of neurons. As abnormal PrP aggregates build up in the brain, they sometimes clump into distinctive masses of amyloid.18

This attribute of misfolded PrP—its ability to assemble into amyloid—furnishes telling clues to the nature of the prion. Surprisingly, amyloid-forming proteins also characterize more common age-related neurodegenerative diseases, such as Alzheimer’s disease. While amyloid is obvious under the light microscope (see Figure 1), the amyloid itself may only be the tip of the iceberg; the aberrant proteins often form assemblies that are not amyloid in the strict sense of the word, and in many instances, much smaller clusters of misfolded protein molecules called oligomers have been found to be quite toxic to cells.

Cerebrum - Figure 3 - The Malignant Protein Puzzle (March 2016) (feat)
Figure 3 : The pathological face of Alzheimer’s disease: In a slice of the brain of an Alzheimer patient viewed at high magnification, three spherical clumps of Aβ form senile (Aβ) plaques, and aggregated tau forms flame-shaped neurofibrillary (tau) tangles in surrounding neurons.
 
Image courtesy of 
Lary Walker/Mathias Jucker  

Other Plaques and Tangles

Intriguing similarities, such as the presence of amyloid and relentless decline of brain function, suggested to Gajdusek, Prusiner, and others that the prion diseases might yield insights into the cause of Alzheimer’s, Parkinson’s, and other human neurodegenerative disorders. Virtually all of these maladies involve the appearance of characteristic protein deposits in the brain. For example, in Alzheimer’s disease (the most frequent cause of dementia), a protein called amyloid beta (Aβ) aggregates to create the “senile plaque” formations seen in the gray matter of all Alzheimer’s brains (Figure 3), as well as cerebral amyloid angiopathy, a buildup of amyloid in the walls of brain blood vessels. Another protein called tau also can adopt the amyloid structure, forming neurofibrillary tangles in Alzheimer’s (Figure 3). While both plaques and tangles are necessary to drive Alzheimer’s disease, the prime mover in the degenerative cascade appears to be Aβ.19 In Parkinson’s disease, yet another protein known as α-synuclein assembles into intracellular amyloid clumps called Lewy bodies. The list of diseases and their misshapen proteins continues to grow.11 In each disease, the flawed proteins are associated with distinctive signs and symptoms. But are they, like PrP prion disease, transmissible?  

In the 1960s, Gajdusek’s group began a massive study to address this very question. Specifically, they wanted to know if non-PrP neurodegenerative diseases such as Alzheimer’s are transmissible to nonhuman primates? The outcome was essentially negative.20 In Great Britain, however, a team led by Rosalind Ridley and Harry Baker reported in the early 1990s that Aβ plaques and cerebral amyloid angiopathy are increased in the brains of marmosets several years after injection of Alzheimer brain homogenates into the brain.21 The actual agent that precipitated these amyloid deposits, however, remained uncertain.  

These researchers logically used nonhuman primates to assess the potential transmissibility of Alzheimer’s disease, since close evolutionary relatives are most likely to manifest the same type of disease. Such experiments, however, were hampered by issues of time and cost. Normal laboratory mice and rats were not suitable for these experiments because the chain of amino acids that makes up rodent Aβ differs from that in humans and monkeys; for that and perhaps other reasons, rats and mice do not naturally develop amyloid deposits in the brain as they grow old. In the mid-1990s, however, genetically engineered mouse models were introduced that make human-sequence Aβ. These “transgenic” mice generate amyloid plaques within a matter of months, and thus were widely adopted as the first practical animal models for studying Alzheimer-like Aβ aggregation in the brain.

Testing a Hypothesis

With this important new tool in hand, the two of us set out to test the hypothesis that Aβ-amyloid can be induced to form in the brains of transgenic mice by a mechanism similar to the infectivity of PrP prions. In our earliest studies, we homogenized brain tissue from Alzheimer patients, spun it briefly in a centrifuge to remove larger debris, and injected a small amount (usually one to four millionths of a liter, or microliters) of the clear extract into the brains of transgenic mice expressing human-sequence Aβ. After an incubation period of several months, the mice began to develop Aβ plaques and cerebral amyloid angiopathy in the injected region, similar in many ways to the Aβ amyloid pathology seen in Alzheimer’s. Subsequent experiments in our labs and others have shown that the seeding agent is indeed aggregated Aβ. 11

The mice did not develop full-blown Alzheimer’s disease, which, to the best of our current knowledge, occurs only in humans. Research has shown, however, that at the molecular level, Aβ seeds resemble PrP prions in virtually every way: they consist solely of a particular protein; the seeds vary in size; they resist destruction by high temperature or formaldehyde; they can spread within the brain and to the brain from elsewhere in the body; and different seed structures have different biological properties (variants that are referred to as strains). 11,14

More recently, numerous elegant studies have found that proteins involved in other neurodegenerative diseases also have prion-like properties. These proteins include tau (which forms neurofibrillary tangles in Alzheimer’s disease, CTE, and many other disorders), α-synuclein (which forms Lewy bodies in Parkinson’s disease, Lewy body dementia, and multiple system atrophy), huntingtin (which forms inclusion bodies in Huntington’s disease), and several proteins with prion-like properties that accumulate in such disorders as ALS and frontotemporal dementia. 11,12,22-25

Are Neurodegenerative Proteopathies Infectious?

A growing awareness of the similarities between PrP prions and other protein seeds has revived speculation that Alzheimer’s and other neurodegenerative diseases might be infectious. This question gained recent prominence with a report from a team led by Sebastian Brandner and John Collinge in Great Britain showing that at least one facet of Alzheimer’s disease—Aβ-amyloid formation—appeared to be induced in patients who were treated as children with human growth hormone in order to correct short stature. 26 It was discovered in the mid-1980s that some of the growth hormone used for treatment, which had been isolated from large batches of human pituitary glands collected at autopsy, was contaminated with PrP prions. As a result, some recipients died of Creutzfeldt-Jakob disease many years after their growth hormone treatments had ceased. Brandner, Collinge, and co-workers were able to examine the brains of eight of them who were 36- to 51-years-old at the time of death. In addition to PrP prion pathology, four of the patients also had substantial Aβ accumulation in plaques and cerebral blood vessels, and two others had sparse Aβ deposits.

The appearance of Aβ plaques and vascular amyloid in people at such a young age is quite unusual. The findings strongly suggest that some batches of growth hormone were contaminated with Aβ seeds in pituitary glands that were inadvertently collected from Alzheimer patients. Remarkably, none of the eight subjects had evidence of neurofibrillary tangles, the other defining brain abnormality in Alzheimer’s disease. Because all of them had died of prion disease, we cannot know whether they eventually would have developed Alzheimer’s. If so, the incubation period would likely be at least as long as that of prion disease.

This presumed transmission of Aβ-amyloidosis to humans occurred under extraordinary circumstances—repeated, long-term injections of a hormone derived from pooled human pituitary glands. By sheer good luck, recombinant growth hormone (produced by genetically modified bacteria) became available in 1985, just at the time when the cadaver-derived hormone was confirmed to be contaminated with PrP prions. The recipients were quickly switched to this safer version of the agent. Strangely (or perhaps not), a black market continued to flourish for cadaver-derived growth hormone, sustained in large part by body-builders and other athletes; the cadaver-derived hormone is indistinguishable from that produced by the recipient, and thus is difficult to detect in doping tests. 27

Fortunately, most of the patients treated with growth hormone prior to 1985 have not developed prion disease. It will be important to follow them in the coming years to determine whether they are at higher risk of Alzheimer’s disease and other neurodegenerative disorders involving protein seeds. Interestingly, a team of Swiss and Austrian researchers recently reported a similar induction of Aβ deposition in CJD patients many years after they had received transplants of PrP prion-contaminated dura mater that had been harvested from human cadavers. 28 These studies by no means indicate that Alzheimer’s disease can be transmitted from person-to-person under everyday circumstances; rather, they do provide the first evidence that the aggregation of a protein other than PrP might be induced in the human brain by exogenous seeds. Just as cancer cells can occasionally transmit disease from one animal to another, the same appears to be true—under exceptional circumstances—for some pathogenic protein seeds.

Promise and Pitfalls of the Prion Paradigm

In Alzheimer’s and other non-PrP neurodegenerative diseases, malignant protein seeds arise from normally generated proteins inside the body, just as malignant cells stem from normal cells in cancer. Nature also has exploited the prion mechanism for beneficial ends; proteins that form prion-like aggregates handle functions ranging from information transfer in yeast 29 to the storage of peptides 30 and the consolidation of memory 31 in mammals. In light of these discoveries, we have argued that the term “prion” should be re-defined as a “proteinaceous nucleating particle” to stress the molecular process of seeded protein aggregation (nucleation) that is common to all of these phenomena. 14 By removing the disquieting word “infectious,” the new definition accommodates the many instances in which such proteins are not infectious by any customary definition of the term.

Recent research has brought into clearer focus the devastating role of malignant proteins in diverse diseases. Infectivity is undoubtedly an important characteristic of PrP prions, particularly in some nonhuman species. Chronic wasting disease, for example, is rapidly spreading among members of the deer family in western North America. 32 In humans, though, most cases of PrP prion disease do not result from infection. Because prions achieved notoriety largely due to their infectivity, this peculiar feature has colored our view of all cases of PrP prion disease, whether they are caused by infection or not. In light of the history of the prion concept, one has to wonder how we would view cancer if the first malignancy discovered had been devil facial-tumor disease, and only later did we learn that most cancerous cells actually develop within the body of the affected organism. Would we now consider all cancers to be potentially infectious? And at what cost to the patients and those who care for them? Our perception of disease, and the language we use to define it, must continually adapt to new information. By highlighting the molecular properties of malignant proteins, the evolving prion concept will help to guide future experimental strategies for defeating a multitude of intractable conditions.

Financial Disclosure : The authors have no conflicts of interest to report.

 

References

 

1              Bender, H. S., Marshall Graves, J. A. & Deakin, J. E. Pathogenesis and molecular biology of a transmissible tumor in the Tasmanian devil. Annu Rev Anim Biosci2, 165-187, doi:10.1146/annurev-animal-022513-114204 (2014).

2              Strakova, A. & Murchison, E. P. The cancer which survived: insights from the genome of an 11000 year-old cancer. Curr Opin Genet Dev30, 49-55, doi:10.1016/j.gde.2015.03.005 (2015).

3              Metzger, M. J., Reinisch, C., Sherry, J. & Goff, S. P. Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams. Cell161, 255-263, doi:10.1016/j.cell.2015.02.042 (2015).

4              Schwartz, M. How the Cows Turned Mad.  (University of California Press, 2003).

5              Cuille, J. & Chelle, P.-L. La maladie dite tremblante du mouton est-elle inoculable? Comptes Rendus de l'Academie des Sciences203, 1552-1554 (1936).

6              Gajdusek, D. C. Unconventional viruses and the origin and disappearance of kuru. Science197, 943-960 (1977).

7              Alper, T., Cramp, W. A., Haig, D. A. & Clarke, M. C. Does the agent of scrapie replicate without nucleic acid? Nature214, 764-766 (1967).

8              Griffith, J. S. Self-replication and scrapie. Nature215, 1043-1044 (1967).

9              Prusiner, S. B. Madness and Memory.  (Yale University Press, 2014).

10           Couzin-Frankel, J. Scientific community. The prion heretic. Science332, 1024-1027, doi:10.1126/science.332.6033.1024 (2011).

11           Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature501, 45-51, doi:10.1038/nature12481 (2013).

12           Prusiner, S. B. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet47, 601-623, doi:10.1146/annurev-genet-110711-155524 (2013).

13           Walker, L. C. & Jucker, M. Seeds of dementia. Sci Am308, 52-57 (2013).

14           Walker, L. C. & Jucker, M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci38, 87-103, doi:10.1146/annurev-neuro-071714-033828 (2015).

15           Lansbury, P. T., Jr. & Caughey, B. The chemistry of scrapie infection: implications of the 'ice 9' metaphor. Chem Biol2, 1-5 (1995).

16           Imran, M. & Mahmood, S. An overview of human prion diseases. Virology journal8, 559, doi:10.1186/1743-422X-8-559 (2011).

17           Imran, M. & Mahmood, S. An overview of animal prion diseases. Virology journal8, 493, doi:10.1186/1743-422X-8-493 (2011).

18           DeArmond, S. J., Ironside, J. W., Bouzamondo-Bernstein, E., Peretz, D. & Fraser, J. R. in Prion Biology and Diseases   (ed S. B. Prusiner)  777-856 (Cold Spring Harbor Laboratory Press, 2004).

19           Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science297, 353-356, doi:10.1126/science.1072994 297/5580/353 [pii] (2002).

20           Goudsmit, J. et al. Evidence for and against the transmissibility of Alzheimer disease. Neurology30, 945-950 (1980).

21           Baker, H. F., Ridley, R. M., Duchen, L. W., Crow, T. J. & Bruton, C. J. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol8, 25-39 (1994).

22           Brettschneider, J., Del Tredici, K., Lee, V. M. & Trojanowski, J. Q. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci16, 109-120, doi:10.1038/nrn3887 (2015).

23           Goedert, M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science349, 1255555, doi:10.1126/science.1255555 (2015).

24           King, O. D., Gitler, A. D. & Shorter, J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res1462, 61-80, doi:10.1016/j.brainres.2012.01.016 (2012).

25           Ayers, J. I., Fromholt, S. E., O'Neal, V. M., Diamond, J. H. & Borchelt, D. R. Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Acta Neuropathol, doi:10.1007/s00401-015-1514-0 (2015).

26           Jaunmuktane, Z. et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature525, 247-250, doi:10.1038/nature15369 (2015).

27           Holt, R. I. & Sonksen, P. H. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol154, 542-556, doi:10.1038/bjp.2008.99 (2008).

28           Frontzek, K., Lutz, M. I., Aguzzi, A., Kovacs, G. G. & Budka, H. Amyloid-beta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Wkly146, w14287, doi:10.4414/smw.2016.14287 (2016).

29           Wickner, R. B. et al. Yeast prions: structure, biology, and prion-handling systems. Microbiol Mol Biol Rev79, 1-17, doi:10.1128/MMBR.00041-14 (2015).

30           Maji, S. K. et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science325, 328-332, doi:10.1126/science.1173155 (2009).

31           Fioriti, L. et al. The Persistence of Hippocampal-Based Memory Requires Protein Synthesis Mediated by the Prion-like Protein CPEB3. Neuron86, 1433-1448, doi:10.1016/j.neuron.2015.05.021 (2015).

32           Haley, N. J. & Hoover, E. A. Chronic wasting disease of cervids: current knowledge and future perspectives. Annu Rev Anim Biosci3, 305-325, doi:10.1146/annurev-animal-022114-111001 (2015).

 



Comments


The Malignant Protein Puzzle-CARNOSINE for research as support therapy

Carlos Oliveira

3/22/2016 12:50:54 PM

Most neurodegenerative diseases (AD,PD,etc) SHARES COMMON PATHOLOGICAL FEATURES as peroxinitrites accumulation , mitochondrial dysfunction,glycation,heavy metal acumulation,brain energy deprivation,neuroinflammation ,and some diseases have a prion-like spreads, etc.As Support Therapy (in microdoses under physician prescription), researchers could deeply study the nutraceuticals CARNOSINE, and ACETYL L CARNITINE (so called ALCAR).About the very interesting article :"The Malignant Protein Puzzle" , that shows "similarities between PrP prions and other protein seeds" that "has revived speculation that Alzheimer’s and other neurodegenerative diseases might be infectious" (or "behaves as infections"(?)) maybe,as a suggestion , the nutraceutical supplement CARNOSINE , can fits to research with prion-like diseases , as we can read in the articles bellow: a) "Zinc ,Copper and Carnosine Attenuate Neurotoxicity of Prion Fragment" - Metallomics 2011 - Masahiro Kawahara, Hironari Koyama, Tetsuya Nagata Yutaka Sadakane ,where we can read : " Prion diseases are progressive neurodegenerative diseases that are associated with the conversion of normal cellular prion protein (PrP(C)) to abnormal pathogenic prion protein (PrP(SC)) by conformational changes. Prion protein is a metal-binding protein that is suggested to be involved in metal homeostasis. We investigated here the effects of trace elements on the conformational changes andneurotoxicity of synthetic prion peptide . CARNOSINE significantly INHIBITED both, the BETAMYLOID acumulation and the neurotoxicity of PRION protein. CARNOSINE MIGHT BECOME A CANDIDATE FOR THERAPEUTIC TREATMENTS FOR PRION DISEASES." b) "Involvement of Trace Elements in the Pathogenesis of Prion Diseases. - Curr Pharm Biotechnol. 2014 - Mizuno D, Koyama H, Ohkawara S, Sadakane Y, Kawahara M , where we can read : "Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrP(C)) into an abnormal pathogenic prion protein (PrP(Sc)) It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer's disease. Roles of CARNOSINE as a candidate NEUROPROTECTIVE substance use in PRION diseases are also discussed." The nutraceutical CARNOSINE is a peroxinitrites scavenger,a heavy metal chelator,and anti-glycating agent,has the potential to lowers betamyloid accumulation in Alzheimer disease, lowers alpha-synuclein accumulation in Parkinson disease and in Dementia of Lewy Bodies, enhances mitochondrial function ,gives neuroprotection against neuroinflammation ,and CARNOSINE LOWERS THE PRION-LIKE SPREADS,that can happens inside the brain of AD,PD and DLB patients.

proteinopathy

Vincent M Tedone MD

3/17/2016 8:54:16 AM

Extracellular glutamate kills contiguous cells. V Teichberg MD Weizman Institute 90 % of amyloid plaque had + bacterial cultures. 80 % of these cultures were Treponema Denticola, a spirochete and pathogen in gum disease. B. Borrelia, a spirochete, added to human nerve cells causes TAU inclusion bodies. Eva Sapi PhD Could the inclusion bodies be Cell Debris? Could the spread of cell death be due to glutamate? Could the initial cause of cell death be due to a spirochete?

Glutamate

Lary Walker

3/6/2016 7:43:56 PM

We did not remove glutamate, but specific removal of Abeta by antibodies, which leaves glutamate (and other substances) in the extract, eliminates the seeding of abeta deposition. Control brain extracts from normal subjects intrinsically lacking aggregated Abeta also fail to seed.

Protein inclusion bodies

Vincent M Tedone MD

3/2/2016 10:59:00 AM

Did you remove glutamate from the substances you injected into the brain?


About Cerebrum

 
Bill Glovin, editor
Carolyn Asbury, Ph.D., consultant

Scientific Advisory Board
Joseph T. Coyle, M.D., Harvard Medical School
Kay Redfield Jamison, Ph.D., The Johns Hopkins University School of Medicine
Pierre J. Magistretti, M.D., Ph.D., University of Lausanne Medical School and Hospital
Robert Malenka, M.D., Ph.D., Stanford University School of Medicine
Bruce S. McEwen, Ph.D., The Rockefeller University
Donald Price, M.D., The Johns Hopkins University School of Medicine
Charles Zorumski, M.D., Washington University School of Medicine

Do you have a comment or question about something you've read in CerebrumContact Cerebrum Now.